title: Classical polyarteritis nodosa and microscopic polyangiitis--a clinicopathologic study.
abstract: OBJECTIVE
  To describe the clinical spectrum, laboratory features, histopathological findings and treatment outcome in patients with classical polyarteritis nodosa (PAN) and microscopic polyangiitis (MPA).
  
  
  METHODS
  Patients with PAN and MPA seen at a large teaching hospital in north India over a period of five years (1994-99) were included in the present study.
  
  
  RESULTS
  We encountered five patients with PAN and six patients with MPA during the study period. Of the five patients with PAN, two had systemic disease while three had limited PAN. The patients with limited PAN included two with cutaneous PAN and one with PAN confined to the nerves. Constitutional symptoms, musculoskeletal complaints, peripheral neuropathy and skin lesions dominated the clinical picture. Fifty percent of the MPA patients presented as pulmonary renal syndrome. All the patients with PAN were HBsAg and ANCA negative and had normal urinalysis findings. In contrast, all patients with MPA demonstrated an active urine sediment and 83.3% were pANCA positive. Some of the rare features encountered by us were the presence of antiphospholipid syndrome and extensive interstitial lung disease in MPA, and spontaneous recovery in one patient with systemic PAN. Treatment outcome was better in PAN as compared with MPA.
  
  
  CONCLUSIONS
  The clinical spectrum of PAN and MPA is quite varied. A good outcome is possible with the use of corticosteroids and cyclophosphamide.
authors: Department of Medicine, All India Institute of Medical Sciences, New Delhi.
authors: R
authors: R
authors: Handa
authors: J P
authors: JP
authors: Wali
authors: S D
authors: SD
authors: Gupta
authors: A K
authors: AK
authors: Dinda
authors: P
authors: P
authors: Aggarwal
authors: N
authors: N
authors: Wig
authors: A
authors: A
authors: Biswas
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007223:Infant; D007668:Kidney / Q000473:pathology; D008168:Lung / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010488:Polyarteritis Nodosa / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*; D011239:Prednisolone / Q000627:therapeutic use; D011379:Prognosis; D011446:Prospective Studies; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed; D014657:Vasculitis / Q000188:drug therapy / Q000276:immunology / Q000473:pathology*
chemical_list: D000893:Anti-Inflammatory Agents; D019268:Antibodies, Antineutrophil Cytoplasmic; D003520:Cyclophosphamide; D011239:Prednisolone